Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This pre-operative window of opportunity study will use functional imaging and serological investigations to assess whether atovaquone significantly reduces tumour hypoxia in patients with non-small cell lung cancer.


Open label window of opportunity study


Patients with suspected non-small cell lung cancer (NSCLC)


  • To investigate whether atovaquone reduces tumour hypoxia.


  • To further investigate whether atovaquone reduces tumour hypoxia.Late SBRT toxicity (>1 month to 6 months post-surgery)
  • To determine whether atovaquone results in a change in tumour perfusion.
  • To determine whether serological markers of hypoxia may replace hyp-PET-CT imaging in future studies of hypoxia modification.
  • To determine reproducibility of hyp-PET-CT, perfusion CT, serological tests, DWI-MRI and DCE-MRI


Open to recruitment: 05 May 2016

Planned accrual completion: 31 October 2018

Trial duration: 30 Months